Biotech Values

[biocqr]

RVNC > Wells Fargo analyst questions 40 unit dosing vs FDA draft guidance of 20 units for Botox...

Fine Lines: Why Allergan’s Botox Ain’t Beat
https://www.barrons.com/articles/fine-lines-why-allergans-botox-aint-beat-1512574882?mod=BOL_da_rta

Wells Fargo's David Maris also reiterated an Outperform rating on Allergan shares following the news, writing that the stock sold off too much:

While this is good news for RVNC, the data remains to be seen in detail and at this point is it unclear how significant a competitor RVNC's product could be to AGN's Botox. While RT002 showed statistically significant results at week 24 versus placebo in a key secondary endpoint, the measurement of this endpoint does not seem to match the FDA's published draft guidance and it is unclear if the data will be enough to get a 6month duration claim on the RT002 label. It is also unclear to us if the longer duration of efficacy is driven by Revance's unique formulation technology or the larger dosing (RT002 is 40 units while Botox is 20 units). We believe the patient and physician loyalty programs and bundling discounts which AGN offers for its wide range of aesthetics franchises will be key to AGN's defense, but we also believe the aesthetics market has room to grow, with current penetration at approximately 10%. Given the potential launch timing for RT002 and AGN's strong dominance in the neurotoxin market, we believe the reaction to AGN's shares (which closed 1.57% vs the S&P 500's 0.19%) on this news is overdone.